Aurobindo Pharma Limited (NSE: AUROPHARMA) announced today that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg, a generic equivalent of QVAR® Inhalation Aerosol 40 mcg and 80 mcg, marketed by Teva Branded Pharmaceutical Products R&D LLC. This marks Aurobindo’s first metered-dose inhaler (MDI) product, signifying a significant milestone in the company’s expansion into complex respiratory therapies and strengthening its capabilities in the inhalation segment.

Manufacturing and Market Potential

The product will be manufactured at Aurobindo Pharma’s Raleigh facility in North Carolina, owned by its wholly-owned step-down subsidiary Aurolife Pharma LLC. The US market for the approved product and newer versions of the reference product, QVAR® Redi Haler, was estimated at US$301 million for the twelve months ended July 2026, according to IQVIA.

Therapeutic Benefits

Beclomethasone Dipropionate HFA Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Indicated for asthma patients who require systemic corticosteroid administration, where adding Beclomethasone Dipropionate HFA Inhalation Aerosol may reduce or eliminate the need for the systemic corticosteroids.

Building on our leadership in Generics, we are now expanding into complex inhalation therapies to create the next wave of differentiated growth in the US market, stated Aurobindo Pharma Limited.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Aurobindo Pharma Limited

Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Aurobindo rises 14.1% over three months, with buying pressure holding steady. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 94% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 10.7%, profits at 22.1%, and the PEG sits at 1.19 — below its growth rate. That combination is rare. Check Fundamentals of Aurobindo Pharma Limited.

Aurobindo Pharma Limited (NSE: AUROPHARMA) is pleased to announce that Lannett Company LLC, a wholly-owned subsidiary, has launched the generic equivalent of Advair Diskus® (fluticasone propionate and salmeterol inhalation powder), a product of GSK plc, in the US market. This marks the first product from Aurobindo’s inhalation pipeline to be commercialized in the US, reflecting the company’s ongoing focus on expanding its portfolio of complex and differentiated inhalation products.

Advair Diskus® for Asthma and COPD

Advair Diskus® in combination therapy is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). This launch is a significant milestone for Aurobindo Pharma as it continues to build its robust portfolio in the respiratory therapeutic area.

Global Pharmaceutical Leader

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients globally in over 150 countries. With 30+ manufacturing and packaging facilities approved by leading regulatory agencies, Aurobindo Pharma remains committed to delivering high-quality, affordable medications worldwide.

For more information, please visit www.aurobindo.com. For further inquiries, contact Investor Relations | Corporate Communications at Phone: +91 40 667 51211 | 66725000, Email: ir@aurobindo.com.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Aurobindo Pharma Limited

Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Aurobindo gains 15.3% over three months and trades near its 52-week highs. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 94% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 10.7%, profits at 22.1%, and the PEG sits at 1.15 — below its growth rate. That combination is rare. Check Fundamentals of Aurobindo Pharma Limited.

Aurobindo Pharma Limited (NSE: AUROPHARMA) announced on June 2, 2026, that its subsidiary, Aurobindo Pharma USA, Inc., received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC. This strategic move is valued at $250 million on a cash-free, debt-free basis and includes normalized working capital. The acquisition is expected to close before the end of June 2026, significantly enhancing Aurobindo USA’s product offerings in complex, non-opioid controlled substances.

Strategic Expansion

The acquisition of Lannett, a Pennsylvania-based generic pharmaceutical company, will add a U.S.-based manufacturing facility in Seymour, Indiana, to Aurobindo USA’s network. This facility has the capacity to scale production to approximately 4 billion doses annually, strengthening Aurobindo USA’s domestic manufacturing footprint. The enhanced capacity aligns with U.S. policy priorities aimed at improving supply chain resilience and increasing domestic pharmaceutical production.

Immediate and Long-term Benefits

The transaction is anticipated to be immediately accretive to Aurobindo Group’s earnings per share. In addition to near-term financial benefits, the acquisition is expected to generate meaningful cost efficiencies, SG&A synergies, and operational integration advantages. It will also expand Aurobindo USA’s portfolio with a differentiated pipeline of complex generics and controlled substances, supporting sustainable long-term growth.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Aurobindo Pharma Limited

Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Aurobindo gains 16.0% over three months and trades near its 52-week highs. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gives back 1.3% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 10.7% and profits at 22.1%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Aurobindo Pharma Limited.